Pulmonary eosinophilia associated to treatment with natalizumab
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Curto, Elena
- dc.contributor.author Munteis-Olivas, Elvira
- dc.contributor.author Balcells Vilarnau, Eva, 1967-
- dc.contributor.author Domínguez Álvarez, Marisol
- dc.date.accessioned 2023-12-11T06:49:32Z
- dc.date.available 2023-12-11T06:49:32Z
- dc.date.issued 2016
- dc.description.abstract Natalizumab (Tysabri(®)) is a leukocytes chemotaxis inhibitor that decreases the leukocytes passage through the hematoencephalic barrier and it is currently used in relapsing-remitting forms of multiple sclerosis (MS). We present a patient with allergic rhinoconjunctivitis diagnosed with MS who started treatment with natalizumab. She began to show mild asthmatic symptoms until she needed admission to the hospital due to respiratory insufficiency. Blood tests showed peripheral eosinophilia and the thoracic computed tomography scan demonstrated pulmonary infiltrates. The bronchoscopy with the bronchoalveolar lavage resulted in eosinophilic alveolitis. No evidence of bacterial, fungal and parasitic infection, connective tissue disease, or vasculitis were observed. After discontinuation of natalizumab, the patient improved without other treatments. As MS is a prevalent disease and the use of natalizumab is increasing, we consider important to point out that this drug can be associated with pulmonary eosinophilia, especially in patients with allergic rhinoconjunctivitis or asthma.
- dc.format.mimetype application/pdf
- dc.identifier.citation Curto E, Munteis-Olivas E, Balcells E, Dominguez-Alvarez MM. Pulmonary eosinophilia associated to treatment with natalizumab. Ann Thorac Med. 2016 Jul-Sep;11(3):224-6. DOI: 10.4103/1817-1737.185762
- dc.identifier.doi http://dx.doi.org/10.4103/1817-1737.185762
- dc.identifier.issn 1817-1737
- dc.identifier.uri http://hdl.handle.net/10230/58490
- dc.language.iso eng
- dc.publisher Medknow Publications
- dc.relation.ispartof Annals of Thoracic Medicine. 2016 Jul-Sep;11(3):224-6
- dc.rights © 2016 Annals of Thoracic Medicine. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-sa/3.0/
- dc.subject.keyword Multiple sclerosis
- dc.subject.keyword Natalizumab
- dc.subject.keyword Pulmonary eosinophilia
- dc.title Pulmonary eosinophilia associated to treatment with natalizumab
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion